Lung Cancer

Lecia V. Sequist, MD, medical oncologist, associate professor, Massachusetts General Hospital, Harvard Medical School, discusses the overall survival analysis of the LUX-Lung 3 and LUX-Lung 6 trials.

Biopsies were found to be the most costly tool used in lung cancer diagnosis, and may be performed too frequently based on negative test results and adverse events.

David R. Gandara, MD, from UC Davis Comprehensive Cancer Center, discusses the future of clinical trial designs.

The FDA has granted a breakthrough therapy designation to pembrolizumab (Keytruda), an anti-PD-1 therapy, for the treatment of patients with non-small cell lung cancer (NSCLC) who are EGFR mutation- or ALK rearrangement-negative and whose disease has progressed on or following platinum-based chemotherapy.

Suresh S. Ramalingam, MD, discusses results from a phase II trial exploring the potential of veliparib as a treatment for patients with squamous cell NSCLC.

The treatment of patients with non-small cell lung cancer (NSCLC) who harbor an actionable mutation in EGFR or ALK continues evolve, as clinical trials begin exploring next-generation agents and combination strategies.

ASCO has endorsed the CAP/IASLC/AMP guideline on molecular testing for patients with lung cancer, which recommends EGFR and ALK testing for all patients with lung adenocarcinoma or mixed histology with an adenocarcinoma component.

Balazs Halmos, MD, section chief of Thoracic Oncology at New York-Presbyterian Hospital/Columbia University Medical Center, comments on the detection of actionable mutations in patients with lung cancer.

A clinical trial collaboration between Novartis and BMS has resulted in the establishment of several novel combination trials involving the PD-1 inhibitor nivolumab and targeted therapies against ALK, c-MET, and T790M for patients with NSCLC.

The highly selective ALK inhibitor AP26113 has been granted a Breakthrough Therapy Designation by the FDA for the treatment of patients with ALK-positive metastatic NSCLC who received prior treatment with crizotinib.

Christian Rolfo, MD, PhD, MHBA, head, phase I clinical trials unit, Antwerp University Hospital, Belgium, discusses the potential utility of ceritinib.

Roy S. Herbst, MD, PhD, professor, Yale Cancer Center, chief of medical oncology, Smilow Cancer Hospital at Yale-New Haven, discusses next generation lung cancer trials.

As director of the Yale Cancer Center and physician-in-chief of the Smilow Cancer Hospital at Yale-New Haven, Thomas J. Lynch Jr, MD, wears many hats. And, having built a career united around two abiding goals of clinical discovery and personalized patient care, that's just the way he likes it.

Treatment with crizotinib (Xalkori) demonstrated an overall response rate (ORR) of 72% in patients with ROS1-rearranged non–small cell lung cancer (NSCLC), according to phase I data presented at the 2014 ESMO Congress and published in The New England Journal of Medicine.

Susan Galbraith, MD, PhD, head, Oncology Innovative Medicine, AstraZeneca, discusses updated data from the ongoing phase I/II AURA study looking at AZD9291 for NSCLC.

Almost 60% of patients with advanced non–small cell lung cancer experienced tumor shrinkage when treated with the PD-L1 inhibitor pembrolizumab.

Vintafolide in combination with docetaxel showed improvements in PFS and OS compared with single-agent docetaxel as second-line treatment of patients with folate receptor–positive NSCLC.

Patients with advanced lung cancer had improved appetite, less weight loss, and a significant increase in lean body mass when treated with the ghrelin agonist anamorelin.

Peter Emtage, discusses a phase I open-label study evaluating the safety and tolerability of MEDI4736 in combination with tremelimumab for the treatment of patients with advanced non-small cell lung cancer.

Niraj Mehta, MD, Radiation Oncologist, 21st Century Oncology, discusses the reliability of automated segmentation for lung volumes in breast, lung, and esophageal cancers.

Timing of metastatic development, lymph node involvement, and type of disease all factor into the overall survival rate of patients with stage IV NSCLC.

Sai-Hong Ignatius Ou, MD, PhD, Health Science Associate Clinical Professor, University of California, Irvine, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, California, discusses data on alectinib as treatment for patients with non-small cell lung cancer (NSCLC) with brain metastases.

James CH Yang, MD, PhD, from the National Taiwan University Hospital, discusses the future of lung cancer treatment.

Amy P. Abernethy, MD, PhD, associate professor, School of Nursing, director, Duke Center for Learning Health Care, Duke University School of Medicine, discusses anamorelin for the treatment of cancer anorexia-cachexia.

Naiyer A. Rizvi, MD, an associate attending physician, Memorial Sloan Kettering Cancer Center, discusses pembrolizumab (MK-3475) for the treatment of non-small cell lung cancer (NSCLC).